Our website uses cookies to distinguish you from other users of our website. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Asia Pacific +65 6212 1000. Scott brings to RAVen 20 years of experience working with clients and portfolio companies to complete transactions including multiple IPOs and acquisitions of portfolio companies. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Michael Sherman is a Venture Partner at RA Ventures. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. Prithviraj comes to RA from CVS Health, where he was Director of HealthHUB Product Technology Strategy and Enablement. from Harvard College and an M.B.A. from Harvard Business School. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Dan studied Network Communications & Information Services at Lincoln Technical. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. Her primary responsibilities are to assist with all finance operations related to the Firm. Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to Longitude Capital, Cristina held an Associate Analyst role in Biotechnology Equity Research at Cowen. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Americas +1 212 318 2000. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. Kyle's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. 4. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Prior to RA Capital, Tyler worked as a freelance graphic designer. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. Michael holds a B.S. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). The film delves into the psychological roots of Hook's anger, Peter Pan's everlasting childhood, and Wendy's reluctance to face adulthood. Ramaswamy, who just turned 30, has bigger aspirations. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. Lorena Chen is a Fund Controller at RA Capital Management. He also provided additional system administration and training for the desktop engineering team. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . Steve's survey is fascinating. Prior to CVS Health, Prithviraj was a Senior Research Associate at the Gerson Lehrman Group. Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Support. Michael Calore is the Director of Investor Relations at RA Capital Management. Joe DeMaio is IT Operations Associate at RA Capital Management. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Prior to co-founding Therapeutics Alliances, Nadim worked in NYUs Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Prior to joining RAVen, Habib spent five years as President and CEO at Acceleron Pharma. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Cristina Montero is an Associate Director within the TechAtlas division of RA Capital Management. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. EXCLUSIVE : Robert Morgan's Talaria . In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Mike earned his MBA from the Darden Graduate School of Business Administration. Cristina holds a Bachelor of Arts in Biochemistry from Mount Holyoke College and a PhD in Cell Biology and Epigenetics from Cornell University and The Rockefeller University. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. In this position, he played a critical role in building Mercks oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. James Schneider is the Deputy General Counsel at RA Capital Management. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Sarah teaches a course at Harvard Law School on venture capital fund formation. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Hearing the stories of how patients couldn't afford the . Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. and Novus Biologicals. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Eric is the Chief Compliance Officer at RA Capital Management. Laura is an Executive Assistant at RA Capital Management. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. He had to juggle the demands of raising a family while also trying to pay for his children's education. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Cameron has a BA in Neurobiology from Harvard University. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Craig Randall is Assistant General Counsel at RA Capital Management and Counsel at RA Ventures, RA Capital's incubator for new companies. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. Mark brings to RAVen more than twenty-five years of leadership experience in the life sciences industryspanning operations, corporate development, legal affairs, and intellectual property. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. James is admitted to practice law in the Commonwealth of Massachusetts. Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). He also holds a B.A. Sris primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Alex has a BS in Chemistry and a Minor in Religious Studies from Davidson College. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. In addition, Michael served on the firm's Luxembourg Board of Directors where he was responsible for accounting and financial reporting. He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). By Matt Grobar. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. Kat Riesen is the VP, Finance at RA Ventures (RAVen). Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. He holds a MS from Northeastern University and a BA from Hamilton College. Craig is admitted to practice law in the Commonwealth of Massachusetts. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Walter has a BS in Biology from Davidson College and a MS in Genetics from University of Georgia. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. Peter Kolchinsky Number of IPOs: 18. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. He earned his MS in Bioinformatics from Boston University. Prior to RA, he served in a dual role at Merck Research Laboratories (MRL). James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. Anthonys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts. Vanderpump Rules' Peter Madrigal's Age. In this role, he will work to evaluate and incubate early-stage therapeutic programs. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Dans primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. In this role, Maryann supports start-up business infrastructure development for newcos as well as provides strategic HR guidance for founding team members. Peter conducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Erichs primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Adam was also an advisor and investor in A Late Quartet, an entrepreneurial feature film centered on a cellist diagnosed with Parkinsons disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Jesse Chen is an EIR at RA Capital. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Prior to Vor, Sadik served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Kate previously served as Health Law Assistant at Mintz. Neil Buckley is an EIR at RA Capital. Prior to external consulting and engineering, he gained experience in Helpdesk Specialist and Systems Administrator roles at Withum and Edelstein and Company, LLP. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Dan Marks is a Principal on the Venture Team at RA Capital Management. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University. Daphne Zohar is the founder and CEO of PureTech. Ed Monaghan is an EIR at RA Capital. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations. His graduate research investigated innate immune responses after intracerebral hemorrhage. Kevin has a ME in Chemistry and Chemical Engineering from Chimie ParisTech in France, a MS in Biotechnology from the Royal Institute of Technology in Sweden, and a PhD in Physics and Chemistry from Paris Sciences et Lettres Research University in France. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Lucas Guevara is a Compliance Counsel at RA Capital Management. Rajeev Shah is a Managing Partner at RA Capital Management. Phi Thach is an Executive Assistant at RA Capital Management. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. "Too old," said a man in his 70s. as a Staff Accountant. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Nadim Shohdy is an EIR at RA Capital. RA Capital and CEO of Arcuate Therapeutics. in Life Science from National Taiwan University, M.S. He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems. Elena has a BA in Molecular, Cellular, Developmental Biology from University of Colorado, Boulder and a PhD in Molecular, Cellular Biology and Biochemistry from Boston University. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. Directed by David Lowery ("The Green Knight") and featuring Law as Captain Hook, the live-action remake leans into the bittersweet coming-of-age theme of J.M. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Prior to RA, Fuad was a Flagship Labs Fellow at Flagship Pioneering. Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. He authored the e-book "The Entrepreneur's Guide to a Biotech Startup". James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Kathryn Spencer is an Executive Assistant at RA Capital Management. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients.
Santa Clara County Mortuary Obituaries,
Rogers Park News,
Articles P